Cancer Fighters Companies By Enterprise Value
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Current Valuation
| Current Valuation | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson and | 0.01 | 1.34 | 0.01 | ||
| 2 | REGN | Regeneron Pharmaceuticals | (0.08) | 2.06 | (0.17) | ||
| 3 | ARGX | argenx NV ADR | (0.06) | 1.69 | (0.10) | ||
| 4 | HALO | Halozyme Therapeutics | 0.33 | 1.45 | 0.48 | ||
| 5 | TGTX | TG Therapeutics | 0.10 | 3.97 | 0.41 | ||
| 6 | BPMC | Blueprint Medicines Corp | 0.01 | 3.64 | 0.05 | ||
| 7 | PTCT | PTC Therapeutics | 0.13 | 2.57 | 0.34 | ||
| 8 | ZLAB | Zai Lab | 0.13 | 3.28 | 0.41 | ||
| 9 | MESO | Mesoblast | (0.08) | 4.51 | (0.37) | ||
| 10 | NVCR | Novocure | (0.29) | 2.91 | (0.85) | ||
| 11 | HCM | HUTCHMED DRC | 0.01 | 3.51 | 0.03 | ||
| 12 | ARRY | Array Technologies | (0.01) | 5.29 | (0.06) | ||
| 13 | IOVA | Iovance Biotherapeutics | (0.28) | 4.24 | (1.20) | ||
| 14 | GERN | Geron | (0.17) | 5.36 | (0.92) | ||
| 15 | CLDX | Celldex Therapeutics | (0.13) | 3.11 | (0.39) | ||
| 16 | HRTX | Heron Therapeuti | 0.13 | 5.56 | 0.73 | ||
| 17 | ANGO | AngioDynamics | 0.05 | 5.73 | 0.31 | ||
| 18 | RIGL | Rigel Pharmaceuticals | 0.06 | 4.47 | 0.25 | ||
| 19 | CRVS | Corvus Pharmaceuticals | (0.14) | 4.53 | (0.64) | ||
| 20 | PBYI | Puma Biotechnology | 0.03 | 4.82 | 0.13 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents. Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.